Levetiracetam Stada Arzneimittel Ag

Levetiracetam, the active ingredient in Levetiracetam Stada Arzneimittel Ag, is an antiepileptic presented as an oral tablet for systemic administration. It is indicated for the treatment of partial‑onset seizures, generalized tonic‑clonic seizures, and myoclonic seizures in patients diagnosed with epilepsy. The medication works by modulating neuronal excitability, helping to reduce seizure frequency.

GNH USA supplies Levetiracetam Stada Arzneimittel Ag as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory support for cross‑border distribution.

Levetiracetam is an antiepileptic medication used to control seizure activity across several epilepsy syndromes.

Partial‑onset seizures: reduces the frequency of focal seizures in patients with epilepsy. Generalized tonic‑clonic seizures: helps prevent convulsive episodes and associated injuries. Myoclonic seizures: decreases the occurrence of rapid muscle jerks characteristic of this seizure type. Adjunct therapy for refractory epilepsy: may be used when other agents are insufficient. Status epilepticus (adjunct): may be considered as add‑on therapy in acute settings. Adjunct in pediatric epilepsy: used under specialist supervision to manage seizures in children.

Levetiracetam may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Dizziness - Fatigue - Headache - Nausea

Serious or Rare Side Effects: - Severe allergic reactions (anaphylaxis, Stevens‑Johnson syndrome) - Mood changes including depression or suicidal thoughts - Severe skin rash - Blood dyscrasias (e.g., neutropenia, thrombocytopenia)

When prescribing Levetiracetam, clinicians should consider several safety measures. - Renal impairment: adjust dose based on creatinine clearance. - Mood monitoring: observe for depression or suicidal ideation. - Discontinuation: taper gradually to avoid seizure worsening. - Pregnancy: risk unknown, use only if benefit outweighs potential risk. - Concomitant CNS depressants: monitor for additive sedation. - Store at room temperature below 25°C: keep in original container, protect from moisture.

Levetiracetam can interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Carbamazepine: may lower levetiracetam plasma levels. - Phenytoin: can decrease levetiracetam concentrations. - Phenobarbital: may reduce levetiracetam exposure.

Moderate Interactions (Monitor Closely): - Valproic acid: potential for increased side‑effects. - Other antiepileptics: additive central nervous system depression. - Oral contraceptives: possible reduction in hormonal efficacy.